PUR 118

Drug Profile

PUR 118

Alternative Names: PUR118

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Pulmatrix
  • Class Anti-inflammatories; Antiasthmatics; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Influenza virus infections

Most Recent Events

  • 12 Apr 2016 Discontinued - Preclinical for Influenza virus infections in USA (Inhalation)
  • 12 Apr 2016 Discontinued - Phase-I for Cystic fibrosis in United Kingdom (Inhalation)
  • 12 Apr 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top